In patients with post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction, ...
Pulnovo Medical, a pioneer in breakthrough therapies for treating Pulmonary Hypertension and Heart Failure, today announced the successful completion of an oversubscribed $100 million strategic ...
New findings reveal pulmonary arterial hypertension may affect the brain early. Learn how inflammation and cognitive decline ...
In a phase 2 trial, treatment with sotatercept shows reduced pulmonary vascular resistance and heart outcomes in patients ...
AllRock Bio, Inc., a clinical-stage biotechnology company focused on advancing impactful therapies for cardiopulmonary and ...
Patients who have heart failure with preserved ejection fraction (HFpEF) and high blood pressure in the lungs (pulmonary ...
Biotech innovator Liquidia, specializing in pulmonary therapies, reported a notable insider sale amid continued growth in its ...
Positive airway pressure therapy is linked with reduced pulmonary arterial pressures in patients with severe obstructive sleep apnea or obesity hypoventilation syndrome.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), announced today that ...
Tectonic Therapeutic is reviving relaxin biology with TX45, targeting Group 2 Pulmonary Hypertension with HFpEF. Check out ...
This life-altering discovery, made after a dramatic collapse during a leisurely bike ride, has prompted her to undertake the ...
AllRock Bio has dosed the first patients in the Phase IIa ROCSTAR clinical trial investigating ROC-101, an oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results